Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jorge E. Cortes, Michael J. Mauro, Michael W.N. Deininger, Charles Chuah, Dong-Wook Kim, Vamsi Kota, Jeffrey Howard Lipton, Philippe H. Rousselot, Dragana Milojkovic, Phillipp D. Le Coutre, Valentin García Gutierrez, Rocco J. Crescenzo, Eric Leip, Fiona An, Nathalie Bouxin, Andreas Hochhaus, Tim H. Brümmendorf, Carlo Gambacorti-Passerini
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, University of Utah, National University of Singapore, Singapore General Hospital, Duke-NUS Medical School, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Winship Cancer Institute, Princess Margaret Cancer Centre, Université de Versailles Saint-Quentin-en-Yvelines, Hammersmith Hospital, Imperial College London, Charité - Universitätsmedizin Berlin, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Pfizer (United States), Multiple Myeloma Research Foundation, Pfizer (France), Jena University Hospital, Universitätsklinikum Aachen, RWTH Aachen University, University of Milano-Bicocca
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889580406